In pharmaceutical manufacturing, the product designation GENERIC PEPTIDES Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable refers to a cGMP-compliant synthetic peptide active pharmaceutical ingredient platform. The model identifier is the peptide sequence code allocated to the master batch record plus a salt-form suffix, commonly -AC for acetate or -HCl for hydrochloride; this document describes the platform specification class rather than a single peptide sequence. The material is intended for use as the active substance in direct compression tablets, hard-gelatin or HPMC capsules, sachet granules, and sterile injectable solutions or lyophilized powders. The API does not contain binders, fillers, preservatives, or bulking agents. Manufacturing is performed under ICH Q7, EU GMP Part II, and 21 CFR 210/211, with release testing executed by a qualified person. Oral-grade packaging is double low-density polyethylene bags inside a sealed foil laminate; injectable-grade packaging is depyrogenated Type I glass vials with elastomeric closures meeting USP <660>, USP <381>, and Ph. Eur. 3.2.9.

The manufacturing route begins with Fmoc solid-phase peptide synthesis on Wang or 2-chlorotrityl resin, followed by acidic cleavage and simultaneous side-chain deprotection. The crude peptide is purified by reversed-phase preparative HPLC on a C18 column with particle size 10 µm and mobile phase consisting of water/acetonitrile with 0.1% trifluoroacetic acid. Counterion exchange to acetate or hydrochloride is performed by ion-exchange chromatography. Lyophilization is conducted at primary drying shelf temperature -20°C to -10°C and secondary drying at 20°C to 30°C, chamber pressure 50–100 µbar, until the water content reaches the route-specific limit. Lyophilization endpoint is confirmed by a pressure rise test of ≤0.1 mbar over 30 min. The use of TFA in cleavage and preparative HPLC creates a residual TFA control requirement; the injectable-grade limit is tightened to ≤0.1% via repeated salt exchange. Published data for this specific configuration is limited when custom peptide sequences deviate from standard homopeptide or short-chain behaviour.

Release Specification Structure and Monograph Alignment

Release testing follows ICH Q6A universal tests with additional peptide-specific tests. Identity is confirmed by reversed-phase HPLC retention time coincidence and electrospray ionization mass spectrometry; the observed monoisotopic mass is within ±0.5 Da of the theoretical value. Assay is performed by HPLC against a characterized peptide reference standard on an anhydrous, salt-free basis; the acceptance range is 95.0–105.0%. Related substances are quantified by area normalization with a reporting threshold of 0.05%, an identification threshold of 0.10%, and unspecified impurities limited to ≤0.10% per ICH Q3A. Residual solvents are tested by headspace gas chromatography under USP <467>; acetonitrile is controlled at ≤410 ppm, dimethylformamide at ≤880 ppm, and methanol at ≤3000 ppm per ICH Q3C. Water content is determined by Karl Fischer titration under USP <921> with limits of ≤5.0% for the oral grade and ≤2.0% for the injectable grade. Elemental impurities follow ICH Q3D and USP <232>/<233>, with permitted daily exposure scaling for Class 1 metals. Microbial examination under USP <61> applies a limit of ≤10 CFU/g total aerobic microbial count and ≤10 CFU/g total yeasts and moulds. Endotoxin testing for injectable-grade material is performed under USP <85> or Ph. Eur. 2.6.14; the limit is ≤0.25 EU/mg or the calculated K/M limit with K=5 EU/kg, whichever is lower.

Direct compression of low-dose peptide tablets requires the powder to meet a flow function coefficient ≥4.6 and a compressibility index ≤25%, as described in USP <1174>. Solid-state characterization includes laser diffraction particle size analysis under USP <429>; a useful oral tablet range is d50 10–50 µm, d10 ≥5 µm, and d90 ≤150 µm. If the peptide is micronized to d90 ≤10 µm to improve blend uniformity, flowability deteriorates and may require 2.0% w/w colloidal silicon dioxide and 0.5% w/w magnesium stearate in a tumble blender operated at 25 rpm for 15 min with fill volume 30–65%. Tablet trials on a rotary press with 10 mm round tooling at turret speed 30–60 rpm and main compression force 8–18 kN have produced friability ≤1.0% under USP <1216> and disintegration ≤15 min in 0.1 N HCl under USP <701> when the formulation includes a superdisintegrant at 2–5% w/w. For capsule filling, the API bulk density is typically 0.15–0.35 g/cm³, which is below the preferred range for a tamping pin filler; wet or dry granulation is therefore used to raise bulk density to 0.40–0.60 g/cm³ and reduce dusting.

What Limits the Transition from Oral-Grade to Injectable-Grade Peptide API?

The transition is limited by pyrogen and particulate burden, residual counterion and solvent profile, water content, and packaging configuration. An oral-grade lot cannot be relabeled as injectable-grade without demonstrating compliance with the injectable release specification. Saturated steam sterilization at 121°C for 15 min is generally unsuitable for peptides because deamidation and aggregation can exceed acceptable limits; therefore, injectable products are prepared by dissolving the API in Water for Injection, prefiltering through a 0.45 µm membrane, and sterilizing through a 0.22 µm filter per USP <71>. Pre-filtration bioburden action limit is ≤10 CFU/100 mL, and the final solution must meet particulate matter limits under USP <788>: not more than 6000 particles per container at ≥10 µm and not more than 600 particles per container at ≥25 µm for small-volume injections. Endotoxin control is the most stringent difference; the injectable-grade material is released with a bacterial endotoxin limit of ≤0.25 EU/mg or stricter. Residual trifluoroacetic acid is limited to ≤0.1% for injectable grade, while oral grade may accept ≤0.5%. Injectable-grade material is packaged under Grade C/ISO 7 conditions with sterile elastomeric closures, whereas oral-grade material is packaged in a conventional solid API warehouse.

Wet granulation for sachet granules and capsule/tablet intermediates is performed in a high-shear granulator equipped with a 600 L bowl, impeller speed 200 rpm, chopper speed 1500 rpm, and binder addition time 5–8 min; endpoint is detected by an impeller power consumption increase of 15–25%. The binder solution is purified water or an aqueous polymer solution at 15–25% w/w relative to dry powder mass. The wet mass is dried in a fluid-bed dryer at inlet air temperature 40–45°C, airflow 1.0–1.5 m/s, and product temperature 28–32°C, to a loss-on-drying limit of ≤2.0%. Particle size after dry screening is typically d50 150–300 µm, which supports flow into a sachet filler with mass variation ≤2.0% RSD. For low-dose granules, peptide content is protected from segregation by a pre-blend stage with a water-soluble filler of similar particle size distribution; produced granules are stored in sealed HDPE containers at 15–25°C and ≤35% RH until filling. The process is not suitable for oxidation-sensitive peptides unless nitrogen blanketing is applied during drying.

Tablet, Capsule, Granule, and Injectable Route Adaptation

Route adaptation depends on the solid-state form, salt stoichiometry, and residual water. Tablets and capsules usually use the acetate or hydrochloride salt with a particle size distribution optimized for blend homogeneity; sachet granules require larger agglomerates to maintain flow and minimize dusty filling. Injectable formulations use the same peptide molecule but apply a sterile, low-endotoxin grade that is reconstituted in Water for Injection and adjusted to pH 4.0–7.4 with 0.1 N HCl or 0.1 N NaOH; osmolality is adjusted to 270–328 mOsm/kg with sodium chloride or mannitol under USP <785>. The table below summarizes route-specific quality targets. Values are typical platform targets and must be justified by the specific peptide monograph, dosage, and administration route.

In capsule and tablet operations, the oral-grade API is commonly blended with a filler such as microcrystalline cellulose, lactose monohydrate, or mannitol; for low-dose peptides with target content ≤1.0 mg per unit, a pre-blend at 1:10 ratio is used before final blending. Dissolution testing for immediate-release capsules is performed using USP <711> apparatus 2 at 50 rpm in 500 mL of 0.1 N HCl or pH 6.8 phosphate buffer. For delayed-release tablet formulations, enteric coating is applied to a 3–5% weight gain with an aqueous methacrylic acid copolymer dispersion; the API is protected from gastric peptidases, but the product must still demonstrate bioavailability in the intended patient population.

Chemical and physical stability are assessed under ICH Q1A(R2); long-term storage for oral grade is 5°C ± 3°C, accelerated storage is 25°C ± 2°C/60% RH ± 5% RH, and injectable-grade material is stored at -20°C ± 5°C with protection from light. The powder is hygroscopic above 60% RH; pre-drying is required before weighing if moisture uptake exceeds 0.5% in 30 min. Avoid contact with strong oxidizing agents and avoid solution pH above 8.0 during preparation because deamidation and methionine oxidation are accelerated. The API is not compatible with non-aqueous depot solvents unless solubility and stability data are generated for the specific peptide.

Synthetic peptide API differs from recombinant peptide APIs because the chemical synthesis route introduces no host cell protein, residual DNA, or fermentation-derived endotoxin. Consequently, release testing omits HCP ELISA and DNA threshold assays and substitutes chiral purity by a validated chiral HPLC method under ICH Q2(R1). Compared with research-grade and reagent-grade peptides, pharma-grade material includes a full release under ICH Q6A and is referenced in a Type II DMF under 21 CFR 314.420 or an Active Substance Master File.

When Injectable-Grade Peptide APIs Require Tight Endotoxin and Residual Solvent Control

Injectable-grade material requires tightened control when the maximum daily dose is high or the product is administered intrathecally. The endotoxin limit is calculated as K/M with K=5 EU/kg for intravenous administration and K=0.2 EU/kg for intrathecal administration per USP <85>. For a 10 mg dose in a 70 kg patient, M is 0.143 mg/kg and the intravenous K/M limit is 35 EU/mg; therefore the default ≤0.25 EU/mg remains the tighter specification. The K/M calculation becomes restrictive only when the maximum dose exceeds 20 mg/kg. Residual acetonitrile is controlled at ≤410 ppm; dichloromethane is controlled at ≤600 ppm per ICH Q3C. For high-dose injectable products, additional preparative lyophilization may be required to meet the solvent exposure calculation. Elemental impurities are controlled with permitted daily exposure according to the maximum daily dose and the parenteral ICH Q3D Table 2 limits.

The following checklist distinguishes the pharma-grade generic peptide API from research-grade and reagent-grade alternatives. The comparison is based on auditable quality systems and release methods.